Clinical trial
Efficacy of the HCVIDDOXIL Regimen in Patients With Newly Diagnosed Peripheral…
NCT00290433 · M.D. Anderson Cancer Center, Other · Completed
Key facts
| NCT number | NCT00290433 |
|---|---|
| Title | Efficacy of the HCVIDDOXIL Regimen in Patients With Newly Diagnosed Peripheral T-Cell Lymphoma |
| Official title | A Phase II Study of the Efficacy of the HCVIDDOXIL Regimen in Patients With Newly Diagnosed Peripheral T Cell Lymphoma |
| Lead sponsor | M.D. Anderson Cancer Center, Other |
| Collaborators | Ortho Biotech, Inc. Industry |
| Status | Completed |
| Phase | Phase 2 |
| Study type | Interventional |
| Conditions | Lymphoma |
| Intervention type | Drug |
| Interventions | Cyclophosphamide, Mesna, Vincristine, Methotrexate, Ara-C, Dexamethasone, G-CSF, Doxil |
| Enrollment | 55 |
| Start date | Sep 1, 2003 |
| Primary completion | Jul 1, 2015 |
| Completion | Jul 1, 2015 |
| First posted | Feb 13, 2006 |
| Last update posted | Sep 23, 2020 |
| Countries | United States |
At a glance
- 1–9 Study sites
- Yes Results posted
- None Linked FDA submissions
Counts are shown as ranges. Exact figures, trends and every underlying record are available in Orca1.
About ClinicalTrials.gov studies
ClinicalTrials.gov is the U.S. National Library of Medicine's registry of clinical studies conducted around the world. Contact and investigator details are not shown here.
Source: U.S. National Library of Medicine (NLM), ClinicalTrials.gov · Source date: